Tinea capitis (scalp ringworm) is a serious fungal infection that affects 3-8% of children in the United States. Children from disadvantaged socioeconomic backgrounds, sub-Saharan African descent, or other groups that have been traditionally disadvantaged within the health care system are most at risk of infection. Current diagnostics (fungal culture and microscopy) are slow, expensive, and require a high level of user expertise. The goal of this project is to develop a point-of-care immunoassay for tinea capitis that is rapid (<15min), accurate, affordable, and deliverable to sites that serve healthcare disparity populations. This project is funded by a Phase I small business innovation research (SBIR) grant from the National Institute of Biomedical Imaging and Bioengineering. Dr. Amanda Burnham-Marusich and Dr. Thomas Kozel are Co-Principal Investigators on the project, which has a collaborative sub-award component to the University of Nevada, Reno School of Medicine.